IDO/TDO Inhibitors
Indoleamine 2,3-dioxygenase 1 (IDO1) and Tryptophan 2,3-dioxygenase (TDO2) are two key enzymes that catalyze the initial and rate-limiting step in the kynurenine pathway, the primary route of tryptophan catabolism. These enzymes convert the essential amino acid tryptophan into N-formylkynurenine, which is then metabolized to kynurenine and other downstream products. In the context of cancer, IDO1 and TDO2 are often highly expressed in tumor cells or immune cells within the tumor microenvironment. Their activity leads to a local depletion of tryptophan and an accumulation of kynurenine. Tryptophan depletion suppresses the proliferation and activation of effector T cells and natural killer (NK) cells, while kynurenine acts as an immunomodulatory metabolite, promoting the differentiation and function of regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs). This dual effect creates an immunosuppressive microenvironment that allows tumor cells to evade immune surveillance and promotes tumor growth and metastasis. Beyond cancer, IDO1 and TDO2 are implicated in chronic inflammatory diseases, autoimmune disorders, and neurological conditions, highlighting their broad immunoregulatory roles.
The therapeutic targeting of IDO1 and TDO2 has garnered significant interest, particularly in immuno-oncology, with the aim of reversing tumor-induced immune suppression. Numerous IDO1 inhibitors, designed as small molecules, entered clinical trials, primarily in combination with immune checkpoint inhibitors (e.g., PD-1/PD-L1 antibodies). Epacadostat, a potent and selective IDO1 inhibitor, was the most advanced compound, progressing to a pivotal Phase 3 trial (ECHO-301) for advanced melanoma in combination with pembrolizumab. However, this trial, along with several others, failed to demonstrate a significant improvement in progression-free survival or overall survival compared to pembrolizumab alone. This outcome led to a significant setback for the IDO inhibitor field, causing many companies to discontinue their IDO1 inhibitor programs. Despite this, research continues for other IDO1 inhibitors (e.g., indoximod, navoximod) and TDO2 inhibitors, as well as dual IDO1/TDO2 inhibitors, often in earlier stages of development. Inhibitors are typically classified as competitive inhibitors (targeting the heme active site) or non-competitive inhibitors, and by their selectivity for IDO1, TDO2, or both.
Key challenges and reasons for the failure of epacadostat include the complexity of the kynurenine pathway and the tumor microenvironment. It is now understood that IDO1 inhibition alone might not be sufficient to overcome the multifaceted immune evasion mechanisms employed by tumors. Potential issues include compensatory upregulation of TDO2, alternative immunosuppressive pathways, and the need for better patient selection based on biomarkers that predict response to IDO inhibition. No IDO/TDO inhibitors have received regulatory approval. To address these challenges, current research focuses on identifying specific patient populations most likely to benefit, developing more potent and selective inhibitors, and exploring novel combination strategies. These include combining IDO/TDO inhibitors with other immunotherapies (e.g., CAR T-cells, vaccines), chemotherapy, or targeted therapies. Furthermore, inhibitors targeting downstream enzymes in the kynurenine pathway or other metabolic pathways are being investigated.
The lessons learned from the IDO inhibitor experience continue to inform the development of next-generation immunomodulatory agents, emphasizing the need for a deeper understanding of tumor immunology and rational combination approaches.
